Radiation Therapy for Prostate Cancer Recurrence After Surgery Using PSMA-PET Guidance
Comparing Standard and Hypofractionated Treatment Approaches
Led by University Medical Center Groningen · Updated on 2024-02-28
538
Participants Needed
13
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying men who have prostate cancer that returned after surgery, specifically those with biochemical recurrence detected by rising PSA levels but no spread to lymph nodes or distant sites. The trial aims to find out if increasing the dose of radiation therapy using a shorter, more intense schedule can improve cancer control compared to the standard radiation treatment. This is a phase III randomized trial led by the University Medical Center Groningen that focuses on men with PSA levels under 1.0 ngmL after radical prostatectomy.
Participants will be assigned to one of two groups one receiving conventional salvage external beam radiation therapy sEBRT delivering 70 Gy total in 35 daily fractions over 7 weeks, or the other receiving hypofractionated sEBRT delivering 60 Gy total in 20 fractions over 4 weeks. The study compares these two radiation schedules to see if the shorter, higher-dose approach offers better outcomes. Both treatments are guided by PSMA-PET imaging to confirm no metastases.
During the study, men will have regular follow-up visits for up to 5 years to monitor progression-free survival and side effects. Researchers will assess acute and late gastrointestinal and genitourinary toxicities, quality of life, metastasis-free survival, prostate cancer-specific mortality, and overall survival. The primary outcome is the 5-year progression-free survival after radiation therapy. Participants will undergo PSA testing, clinical evaluations, and quality of life questionnaires throughout the study period.
CONDITIONS
Brief Title
PSMA-PET Guided Hypofractionated Salvage Prostate Bed Radiotherapy
Research Team
F
F. Staal, MD
P
P. Veldhuijzen van Zanten
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Patients with prostate adenocarcinoma treated with radical prostatectomy
Tumour stage pT2-4, R0-1, pN0, or cN0, cNx with Gleason score available
No lymph node or distant metastases confirmed by recent PSMA-PET scan within 60 days
PSA progression after prostatectomy defined as two consecutive rises with final PSA > 0.1 ng/mL or three consecutive rises
PSA at inclusion less than 1.0 ng/mL
WHO performance status 0-2 at inclusion
Age between 18 and 80 years at inclusion
Signed informed consent prior to registration
You will not qualify if you...
Prior pelvic irradiation, (chemo)hormonal therapy, or orchiectomy
Previous or active invasive cancers other than superficial non-melanoma skin cancers
Positive lymph nodes or distant metastases based on lymphadenectomy or PSMA-PET/CT scan within 60 days
Double-sided metallic hip prosthesis
Inability or unwillingness to understand trial information, provide consent, or complete quality of life questionnaires
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 4 to 7 weeks depending on treatment arm
Participants receive either conventional or hypofractionated salvage external beam radiotherapy to the prostate bed.
Daily visits for treatment sessions during this period
Follow-up
Duration - Up to 5 years after completion of radiotherapy
Participants are monitored for treatment effects, toxicities, and outcomes including quality of life and survival.
Regular follow-up visits as scheduled by the study team
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Study of 177Lu-PSMA as an Additional Treatment for High and Very High Risk Prostate Cancer After Radiation and Hormone Therapy
Phase 1b Study of 177Lu-PSMA-617 With Liver-Directed Therapy for Metastatic Castration-Resistant Prostate Cancer
Using 18F-PSMA-1007 PET-CT to Guide Targeted Focal Therapy for MRI-Invisible Prostate Cancer
A Prospective Phase II Study Evaluating PET-Directed Treatment in Men with Localized Intermediate-Risk Prostate Cancer
Evaluation of 18F-PSMA-1007 PETCT Imaging Safety and Effectiveness in Adult Men with Prostate Cancer
Combining One MR-Guided HDR Brachytherapy and One SABR Treatment
for Favorable Risk Prostate Cancer
in a Phase 23 Study
Study of 4-Aminopyridine to Improve Nerve Recovery After Robot-Assisted Radical Prostatectomy in Men with Prostate Cancer
Phase III Study of 64Cu-GRIP B PET Imaging for Detecting Granzyme B in Adults with Advanced Genitourinary and Other Solid Tumors
Comparison of 68Ga-P16-093 and 68Ga-PSMA-11 PETCT Scans for Detecting Primary Prostate Cancer in Men
Using 68Ga-PSMA PETMRI and mpMRI to Detect Prostate Cancer in Men Aged 40 to 85
Observational Study to Compare Diagnostic Accuracy and Follow-Up Outcomes
PETCT Imaging Using 68Ga-RM26-RGD to Detect Breast, Brain, and Prostate Tumors with GRPR and v3 Receptors
Phase III randomised controlled trial on PSMA PET/CT guided hypofractionated salvage prostate bed radiotherapy of biochemical failure after radical prostatectomy for prostate cancer (PERYTON-trial): study protocol.